Neuroendocrine Tumor Research Advances
Neuroendocrine Tumor Research Advances is a research topic within Epidemiology. Science Explorer counts 44k research works in it since 1950. 13.0% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the epidemiology, classification, management, and treatment of neuroendocrine tumors, with a specific emphasis on pancreatic neuroendocrine tumors. It covers topics such as somatostatin receptor-based imaging and therapy, MEN1 syndrome, peptide receptor radionuclide therapy, genetic mutations associated with these tumors, and survival analysis.
- Neuroendocrine Tumors
- Pancreatic Neuroendocrine Tumors
- Somatostatin Receptor
- MEN1 Syndrome
- Peptide Receptor Radionuclide Therapy
- Gastroenteropancreatic Neoplasms
- Tumor Classification
- Survival Analysis
- Therapeutic Guidelines
- Genetic Mutations
- Research works
- 44k fractional, since 1950
- In the world top 10%
- 5.7k per year above
- Top-10% rate
- 13.0% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +26% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Neuroendocrine Tumor Research Advances research?
By volume, the United States and China publish the most (1.7k and 1.1k works in 2022–2025).
By volume, 2022–2025
- 1 United States 1.7k works
- 2 China 1.1k works
- 3 Japan 607 works
- 4 Italy 410 works
- 5 India 344 works
- 6 Germany 334 works
- 7 United Kingdom 228 works
- 8 France 226 works
- 9 Spain 199 works
- 10 South Korea 163 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Neuroendocrine Tumor Research Advances research?
By volume in 2022–2025, Chinese Academy of Medical Sciences & Peking Union Medical College publishes the most Neuroendocrine Tumor Research Advances research, followed by The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center.
By volume, 2022–2025
- 1 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 55 works
- 2 The University of Texas MD Anderson Cancer CenterUnited States 42 works
- 3 Memorial Sloan Kettering Cancer CenterUnited States 29 works
- 4 Peking Union Medical College HospitalChina 27 works
- 5 Sichuan UniversityChina 27 works
- 6 Mayo Clinic in ArizonaUnited States 26 works
- 7 Istituti di Ricovero e Cura a Carattere ScientificoItaly 26 works
- 8 All India Institute of Medical SciencesIndia 26 works
- 9 Post Graduate Institute of Medical Education and ResearchIndia 23 works
- 10 Sun Yat-sen UniversityChina 19 works
Who are the leading researchers in Neuroendocrine Tumor Research Advances?
The most-cited researchers publishing on Neuroendocrine Tumor Research Advances include Julie R. Brahmer and Larry Rubinstein.
- 1 Julie R. Brahmer United States 3.8k citations
- 2 Larry Rubinstein United States 3.6k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Neuroendocrine Tumor Research Advances research done?
The largest centres of Neuroendocrine Tumor Research Advances research in 2022–2025 are Beijing (China), Tokyo (Japan), Shanghai (China) and New York (United States).
Largest cities, 2022–2025
Where is the best place to study Neuroendocrine Tumor Research Advances?
Among universities, judged by research, Chinese Academy of Medical Sciences & Peking Union Medical College, Vita-Salute San Raffaele University and Carol Davila University of Medicine and Pharmacy score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 60.9 | 12.9% | 8.3× | 55 | +84.2% |
| 2 | Vita-Salute San Raffaele UniversityItaly | 59.9 | 18.5% | 13.4× | 12 | +131.4% |
| 3 | Carol Davila University of Medicine and PharmacyRomania | 55.9 | 15.6% | 9.4× | 10 | +244.0% |
| 4 | Humanitas UniversityItaly | 53.3 | 17.1% | 16.6× | 9 | +86.7% |
| 5 | University of VeronaItaly | 50.7 | 17.7% | 9.2× | 15 | +7.7% |
| 6 | Post Graduate Institute of Medical Education and ResearchIndia | 49.8 | 6.7% | 10.3× | 23 | +78.4% |
| 7 | University of InsubriaItaly | 47.2 | 6.4% | 16.2× | 11 | +131.1% |
| 8 | Cornell UniversityUnited States | 46.6 | 28.7% | 1.9× | 13 | +130.9% |
| 9 | Medical University of SilesiaPoland | 46.1 | 11.0% | 11.3× | 14 | +31.0% |
| 10 | Medical University of ViennaAustria | 42.8 | 10.0% | 7.0× | 15 | +63.5% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Neuroendocrine Tumor Research Advances research growing?
Output in 2018–2022 was 26% higher than in 2013–2017, peaking in 2021. The fastest-growing topics are Neuroendocrine Tumor Research Advances.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.